Artiva Biotherapeutics, Inc. (ARTV) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-84.3%

$0.66

vs $4.19 price

Levered DCF

$0.64

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

4.66

Safe zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-1.25×	-1.94×	-10.08×	-3.61×	-2.94×	-11.76×	0×
P/B	0.95×	1.32×	-1.72×	-1.5×	-2.37×	-9.78×	0×
P/S	0×	978.41×	8.34×	42.79×	105.39×	0×	0×
EV / EBITDA	-1.1×	-3.92×	-9.57×	-2.24×	-0.72×	-10.71×	0×
Gross margin	0.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%
Operating margin	0.0%	-26805.6%	-91.6%	-1213.3%	-2660.9%	0.0%	0.0%
Net margin	0.0%	-23304.0%	-82.7%	-1184.1%	-3587.7%	0.0%	0.0%
Current ratio	8.61×	15.39×	6.53×	4.08×	8.41×	4.53×	2.08×
Debt / equity	0.1×	0.08×	-0.1×	-0.14×	-0.02×	-0.1×	-1.97×
Interest coverage	0×	0×	0×	0×	0×	-91.81×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-76.3%	-31.3%	17.1%	41.5%	80.8%	83.4%	0.0%
Return on invested capital	-74.9%	-33.5%	-31.8%	-53.9%	-35.3%	-76.4%	0.0%
Return on assets	-64.0%	-27.9%	-26.3%	-43.9%	-42.3%	-61.5%	0.0%
Free cash flow yield	-75.7%	-22.7%	-18.1%	-27.1%	-8.1%	-6.6%	0.0%
Earnings yield	-80.0%	-23.8%	-9.9%	-27.7%	-34.0%	-8.5%	0.0%
Enterprise value	$89.1M	$219.7M	$242.8M	$127.9M	$51.8M	$187.7M	$5.9M
Net debt / EBITDA	0.19×	0.46×	1.44×	1.45×	2.22×	1.33×	0×
Cash conversion cycle (days)	-50	212	19	39	85	0	0